Definium Therapeutics, Inc. (DFTX)
NASDAQ: DFTX · Real-Time Price · USD
38.89
+1.16 (3.07%)
At close: Sep 11, 2026, 4:00 PM EDT
38.50
-0.39 (-1.00%)
After-hours: Sep 11, 2026, 7:55 PM EDT
Definium Therapeutics Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Definium Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $67.47. The average 1-year stock price forecast is 73.49% higher than the current stock price, while the lowest is $52 (+33.71%) and the highest is $90 (+131.42%).
Price Target: $67.47 (+73.49%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Definium Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 12 | 12 | 12 | 13 | 14 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 16 | 16 | 16 | 17 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $66 | Buy | Maintains | $66 | +69.71% | Sep 11, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $75 | Buy | Reiterates | $75 | +92.85% | Sep 8, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $64 | Buy | Reiterates | $64 | +64.57% | Sep 2, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $72 | Buy | Maintains | $72 | +85.14% | Aug 31, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $60 | Buy | Maintains | $60 | +54.28% | Aug 31, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
31.42M
EPS This Year
-3.16
from -2.06
EPS Next Year
-1.88
from -3.16
EPS and Forward PE are based on non-GAAP adjusted numbers.